This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
ENPP1 / Ectonucleotide pyrophosphatase/phosphodiesterase family member 1 · IHC design guide
Design Immunohistochemistry for ENPP1
Plan ENPP1 staining in paraffin sections using the membranous pattern seen in selected cells (HPA tissue IHC). Catalog antibody A01342-1 is listed for human IHC at 1–2 μg/ml (datasheet A01342-1); consider the secreted form when interpreting staining (UniProt).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
ENPP1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Membranous staining in selected cells (HPA tissue IHC) | |
| Staining pattern | Membranous in placental stroma, chondrocytes and glands (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A01342-1) | |
| Positive control | Parathyroid gland+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections (standard IHC practice; not target-specific) | |
| Caveat | A secreted form may alter the expected membrane pattern (UniProt) | |
| Regulation | Placenta-enhanced RNA expression (HPA tissue RNA) | |
| Isoform / epitope | No listed isoforms; secreted form lacks the cytoplasmic region (UniProt) |
Section 1
Recommended ENPP1 IHC & IF Protocols
The catalog antibody protocol is supplemented by three published ENPP1 IHC methods covering rabbit knee cartilage, breast carcinoma tissue microarrays, and histological sections (PMC9276012; PMC3783308; PMC5803363).
| Sample | Paraffin-embedded human endometrial cancer tissue; fixative not specified (datasheet A01342-1) |
| Fixation | Image fixative and duration unreported (datasheet A01342-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A01342-1); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A01342-1) |
| Primary antibody | Rabbit anti-ENPP1, 1-2 μg/ml (datasheet A01342-1) |
| Primary incubation | Overnight at 4 °C (datasheet A01342-1) |
| Detection | HRP-conjugated secondary, DAB chromogen (datasheet A01342-1) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | ENPP1-positive staining in glandular cells of parathyroid gland (HPA tissue IHC: High). HPA tissue profile: Membranous expression in a subset of cells including placental stroma, chondrocytes, exocrine pancreas, renal tubules, thyroid and parathyroid gland. No signal in the no-primary control. |
💡Decision noteStart with heat retrieval in EDTA pH 8.0 for the catalog antibody (datasheet A01342-1). The breast carcinoma method used 95 °C for 20 min but did not specify retrieval solution composition (PMC3783308).
Section 2
What Is the Expected ENPP1 Staining Pattern?
ENPP1 is a membrane protein with one transmembrane segment, residues 77–97, and may also be secreted (UniProt P22413 topology; UniProt P22413 processing). In paraffin-section IHC, expect membranous staining in selected cells, including thyroid and parathyroid glandular cells, renal distal tubules and chondrocytes (HPA tissue IHC). HPA rates its tissue pattern Enhanced, while noting medium consistency with RNA expression and a secreted variant that complicates tissue-level comparisons (HPA tissue IHC).
| Distinct membrane staining in thyroid or parathyroid glandular cells, with adjacent cells less stained (HPA tissue IHC). | This fits HPA's High staining in those glandular cells and its description of expression in a subset of cells (HPA tissue IHC). Score the named cell population and its membrane pattern rather than assigning one intensity to the whole section (general IHC practice). |
| Predominantly nuclear staining, without a convincing membrane pattern, in a known-positive cell population. | Nuclear localization does not fit ENPP1's annotated membrane and secreted locations (UniProt P22413 subcellular location; HPA subcellular summary). Treat it as a suspected artefact; check the counterstain and detection controls before scoring it as ENPP1 (general IHC practice). |
| Strong staining throughout HPA-negative cell populations, such as adipocytes or bone-marrow hematopoietic cells (HPA tissue IHC). | HPA reports ENPP1 as Not detected in those named cells (HPA tissue IHC). Widespread staining there raises concern for antibody cross-reactivity or endogenous detection activity; a no-primary control helps distinguish detection background (general IHC practice). |
| Diffuse color across cells and tissue spaces, obscuring individual membrane outlines. | This cannot establish the cell-selective membrane pattern reported by HPA (HPA tissue IHC). Review no-primary staining, blocking, washing and detection conditions; extracellular color alone also needs caution because a secreted ENPP1 form is annotated (general IHC practice; UniProt P22413 processing). |
| No discernible signal in thyroid or parathyroid glandular cells (HPA tissue IHC). | Those cells are useful positive comparators because HPA reports High staining (HPA tissue IHC). A blank comparator makes a negative result elsewhere hard to interpret; review the catalog antibody's IHC-P instructions and the staining controls (general IHC practice). |
💡Expected ENPP1 appearanceCall the section positive when selected glandular cells show clear membrane-associated chromogen, especially the High thyroid or parathyroid signal reported by HPA; diffuse staining of HPA-negative cells or isolated nuclear color is suspect (HPA tissue IHC; UniProt P22413 subcellular location).
| Topology and epithelial polarity (UniProt P22413 topology; UniProt P22413 subcellular location). | ENPP1 has a short cytoplasmic portion, residues 1–76, and an extracellular portion, residues 98–925 (UniProt P22413 topology). UniProt places it on basolateral membranes in polarized epithelia and hepatocytes, so assess membrane position where cell borders are visible (UniProt P22413 subcellular location). |
| Processing and extracellular signal (UniProt P22413 processing). | UniProt annotates a secreted form spanning residues 103–925 and matrix-vesicle targeting in osteoblasts (UniProt P22413 processing; UniProt P22413 subcellular location). Extracellular staining can therefore merit investigation, but it should not replace cell and compartment checks or be assumed specific from position alone (general IHC practice). |
| Cell-specific reference levels (HPA tissue IHC). | HPA reports High glandular-cell staining in thyroid and parathyroid, Medium staining in kidney distal tubules and pancreatic exocrine glandular cells, and Low staining in lung macrophages (HPA tissue IHC). Compare equivalent cells when judging signal, since a faint low-reference population is a weaker positive control (general IHC practice). |
| Interpretive limits of tissue evidence (HPA tissue IHC). | Target-specific fixation effects are not established by the supplied assay evidence. Verify with a matched IHC source before attributing a result to fixation. |
| Antibody-specific validation (HPA antibodies). | HPA lists IHC status as Supported for HPA062066 and Enhanced for CAB032904 (HPA antibodies). These are separate antibody assessments; confirm which reagent generated a reference image before treating its intensity as directly comparable to the catalog antibody (general IHC practice). |
| IF/ICC: should the IHC pattern be expected there? (HPA subcellular summary). | Membrane or secreted localization is a reasonable starting expectation (UniProt P22413 subcellular location; HPA subcellular summary). HPA provides no ICC-IF image cell lines or main-location assignment here, so this IHC tissue record cannot validate an IF/ICC image or establish an IF/ICC staining condition (HPA subcellular summary). |
| Situation | Likely cause | Next action |
|---|---|---|
| Known-positive thyroid or parathyroid cells remain unstained (HPA tissue IHC). | The positive comparator has failed; HPA reports High staining in those cells, but this observation alone does not identify the failed staining step (HPA tissue IHC; general IHC practice). | Check slide integrity, reagent sequence and detection controls, then review the catalog antibody's IHC-P protocol before interpreting other tissue as negative (general IHC practice). |
| Membrane staining is weak in kidney distal tubules (HPA tissue IHC). | HPA reports Medium staining there, so a weaker signal than in its high-staining glandular references may be expected (HPA tissue IHC). | Compare the same cell type across sections and confirm that a high-reference tissue and the detection control worked before adjusting the IHC workflow (HPA tissue IHC; general IHC practice). |
| Broad brown color appears in HPA-negative cells and in the no-primary control (HPA tissue IHC). | Color without primary antibody points to background from the detection workflow; endogenous enzyme activity is one possible cause with enzyme-based chromogenic detection (general IHC practice). | Review the detection system's endogenous-activity blocking step and repeat the no-primary control before calling those cells ENPP1-positive (general IHC practice). |
| Broad staining persists only when primary antibody is added, including adipocytes or bone-marrow hematopoietic cells (HPA tissue IHC). | Those named cell populations are Not detected in HPA; primary-dependent staining raises concern for cross-reactivity or insufficient antibody optimization (HPA tissue IHC; general IHC practice). | Recheck the catalog antibody's IHC-P guidance, assess its staining against a high-reference cell population, and interpret the discordant cells cautiously (HPA tissue IHC; general IHC practice). |
| A strong nuclear pattern dominates while cell membranes are difficult to identify. | The observed compartment conflicts with ENPP1's membrane and secreted annotations; counterstain or nonspecific color may be misleading (UniProt P22413 subcellular location; general IHC practice). | Inspect a no-primary control and the counterstain separately, then score ENPP1 only where the primary-dependent signal has a credible cell and compartment pattern (general IHC practice). |
| Extracellular deposits appear beside weakly stained cells. | A secreted ENPP1 form is annotated, but extracellular color by itself does not identify the deposited material (UniProt P22413 processing; general IHC practice). | Record the deposit separately from membrane staining, compare known-positive cells and controls, and avoid assigning the deposit to ENPP1 from location alone (HPA tissue IHC; general IHC practice). |
Experiment evidence
IHC & IF images showing ENPP1 staining
A01342-1 · IHCIHC analysis of ENPP1/PC1 using anti-ENPP1/PC1 antibody (A01342-1). ENPP1/PC1 was detected in a paraffin-embedded section of human endometri
A01342-1 · IHCIHC analysis of ENPP1/PC1 using anti-ENPP1/PC1 antibody (A01342-1). ENPP1/PC1 was detected in a paraffin-embedded section of human liver can
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000197594-ENPP1/tissue/cerebral+cortex#imid_9474556
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000197594-ENPP1/tissue/colon#imid_9450994
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000197594-ENPP1/tissue/liver#imid_9450995
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000197594-ENPP1/tissue/kidney#imid_9450996
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for ENPP1 IHC & IF
🧪Run parathyroid gland first; its glandular cells should stain (HPA: High in parathyroid glandular cells). Use adipose tissue adipocytes as the negative tissue (HPA: Not detected in adipocytes), and compare nonglandular cells on the parathyroid slide with control background rather than assuming they are ENPP1-negative (HPA: High assigned to glandular cells).
Positive control tissue: Parathyroid gland (Glandular cells, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA carries no ICC-IF cell line for ENPP1; derive a cell-line control from the positive tissue's cell type (Glandular cells) and confirm it by RNA or western blot first.
Technical controls: Run a no-primary (secondary-only) control, a rabbit IgG isotype control matched to the primary’s clonality, and an ENPP1-knockout biological control if available (caption: rabbit anti-ENPP1/PC1; standard IHC specificity controls). Quench endogenous peroxidase and check for residual DAB background in the parathyroid section (caption: HRP/DAB detection; standard chromogenic IHC practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected A01342-1 paraffin-section caption does not state the fixative (caption: fixative unreported). The reported IHC procedure uses heat retrieval in EDTA at pH 8.0; the supplied evidence does not establish whether frozen sections or IF/ICC are easier (caption: EDTA retrieval; HPA subcellular: no ICC-IF image cell lines). Confirm the parathyroid boundary when interpreting staining because adjacent thyroid glandular cells are also strongly positive (HPA: High in thyroid glandular cells).
HPA tissue IHC evidence for ENPP1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — Medium consistency between antibody staining and RNA expression data. At least one protein variant secreted, tissue location of RNA and protein might differ and correlation is complex. Antibody staining in cells/structures not annotated, view images.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Parathyroid gland | Glandular cells | High | Protein (IHC) | HPA → |
| Thyroid gland | Glandular cells | High | Protein (IHC) | HPA → |
| Appendix | Germinal center cells | Medium | Protein (IHC) | HPA → |
| Gallbladder | Glandular cells | Medium | Protein (IHC) | HPA → |
| Kidney | Distal tubules | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | Not detected | Protein (IHC) | HPA → |
| Cerebellum | Cells in granular layer | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced ENPP1 IHC Tips
Troubleshoot ENPP1 staining in paraffin sections by checking retrieval, compartment, cell type and controls before interpreting chromogenic signal (UniProt P22413; HPA tissue IHC).
Which retrieval conditions should I try first for weak ENPP1 staining?
Use heat-mediated antigen retrieval in EDTA at pH 8.0 for this paraffin-section IHC assay (datasheet A01342-1). If staining remains weak, compare retrieval durations on adjacent sections while keeping the antibody concentration, detection chemistry and development time constant (standard IHC practice). The selected image used 2 μg/ml primary antibody overnight at 4°C, providing a documented starting condition for that comparison (datasheet A01342-1). Check tissue integrity and background alongside signal, because excessive heating can damage morphology and reduce interpretability (standard IHC practice). A different buffer or pH should be a documented fallback tested against the EDTA condition, with positive and negative controls in the same run (standard IHC practice).
Could fixation explain weak or uneven ENPP1 staining?
ENPP1-specific sensitivity to fixation is unknown: the selected paraffin-section caption does not state a fixative or fixation duration (datasheet A01342-1). Record the fixative, time to fixation and duration for each specimen before comparing staining across cases (standard IHC practice). If fixation varies, test adjacent sections with the same EDTA pH 8.0 retrieval and 2 μg/ml primary antibody conditions used in the selected image (datasheet A01342-1). Compare preservation of membrane outlines and tissue morphology as well as signal intensity, using a positive control in each run (standard IHC practice). Do not assign a fixation effect to ENPP1 from its tissue distribution or membrane topology alone (HPA tissue IHC; UniProt P22413 topology).
Where should convincing ENPP1 staining appear in a paraffin section?
Prioritise cell-associated membrane staining: ENPP1 has a transmembrane segment at residues 77–97, with most of the protein extracellular (UniProt P22413 topology). In polarized epithelial cells and hepatocytes, basolateral staining is plausible; in bile duct cells and cancer cells, apical cytoplasmic-side localisation is also reported (UniProt P22413 subcellular location). A secreted form spanning residues 103–925 means extracellular signal may occur, but it needs careful assignment to its source cells (UniProt P22413 processing). HPA reports membranous staining in subsets of cells, including renal tubules and chondrocytes (HPA tissue IHC). Compare the signal with cell boundaries and a negative control before calling diffuse cytoplasmic colour specific (standard IHC practice).
How can epitope location change the ENPP1 staining pattern?
Map the catalog antibody’s documented immunogen or epitope before interpreting an unexpected staining compartment; its epitope is not specified in the supplied caption (datasheet A01342-1). ENPP1 has a short cytoplasmic region at residues 1–76 and an extracellular region at 98–925 (UniProt P22413 topology). The reported secreted form begins at residue 103, so an antibody to that shared region could detect membrane-associated and secreted ENPP1 (UniProt P22413 processing). Nine annotated glycosylation sites lie in the extracellular region, but their effect on this antibody’s staining has not been established here (UniProt P22413 glycosylation; datasheet A01342-1). The supplied record lists 0 isoforms; avoid attributing staining differences to an undocumented splice variant (UniProt P22413 isoforms).
How should I check an ENPP1 signal by multiplex immunofluorescence?
Treat multiplex IF as a separate assay requiring its own controls; the supplied catalog image documents chromogenic IHC in a paraffin section (datasheet A01342-1). Pair ENPP1 with a validated marker of the expected cell type, such as a renal distal-tubule marker when examining the HPA-positive kidney compartment (HPA tissue IHC; standard IF practice). Select fluorophores after inspecting unstained tissue autofluorescence, and reserve a spectrally distinct channel for the weaker signal (standard IF practice). For an extracellular epitope, test staining without permeabilisation first; for a cytoplasmic epitope, test controlled permeabilisation, guided by the antibody’s mapped epitope (UniProt P22413 topology; standard IF practice). Include single-stain and secondary-only controls to assess bleed-through and nonspecific fluorescence (standard IF practice).
What should I adjust when ENPP1 IHC has widespread brown background?
Check a no-primary control first to distinguish primary-dependent staining from detection background (standard IHC practice). The selected workflow used 10% goat serum, 2 μg/ml primary antibody overnight at 4°C, a peroxidase-conjugated secondary and DAB (datasheet A01342-1). If background follows the primary antibody, titrate it around the documented concentration and compare wash conditions on adjacent sections (standard IHC practice; datasheet A01342-1). Block endogenous peroxidase for HRP detection and inspect a no-primary section before attributing diffuse DAB to ENPP1 (standard IHC practice). Judge improvements against retained membrane-pattern signal in a positive control, since ENPP1 is reported at the cell membrane (UniProt P22413 subcellular location; standard IHC practice).
How should I score ENPP1 staining across tissue sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the scored compartment and cell population before analysis; HPA describes membranous expression in subsets of cells rather than uniform tissue-wide staining (HPA tissue IHC). For chromogenic IHC, record the percentage of positive target cells and membrane intensity, then calculate an H-score if intensity categories are reproducible (standard IHC practice). If positive cells are sparse, report their density per mm² of viable, annotated tissue alongside the percentage of eligible cells stained (standard IHC practice). Exclude folds, section edges and necrotic areas using the same rules for every specimen (standard IHC practice). Normalise to the relevant cell population or viable tissue area, and keep retrieval, DAB development and imaging settings consistent across cases (standard IHC practice).
How can I distinguish true ENPP1 positivity from staining artefact?
Look for reproducible cell-associated membrane staining in an appropriate population, such as distal renal tubules, and compare it with a negative control (HPA tissue IHC; standard IHC practice). ENPP1 can also be secreted, so extracellular colour alone cannot identify the producing cell without supporting localisation evidence (UniProt P22413 processing; standard IHC practice). Treat staining confined to section edges, folds or necrosis as suspect and inspect matched morphology before scoring it (standard IHC practice). With HRP and DAB detection, a no-primary control helps reveal endogenous enzyme signal or detection-system background (standard IHC practice). Interpret negative cells cautiously: HPA reports subset expression and describes only medium consistency between antibody staining and RNA data (HPA tissue IHC).
Boster reagents
Best ENPP1 / Ectonucleotide pyrophosphatase/phosphodiesterase family member 1 IHC Antibodies
A01342-1 has real IHC images from human paraffin-embedded endometrial cancer, liver cancer, and placenta sections (catalog image captions). No IF/ICC image is supplied (catalog payload).
Real IHC data
Anti-ENPP1/PC1 Antibody ®
Cat # A01342-1
A01342-1 is listed for human IHC, with staining shown in paraffin-embedded endometrial cancer and liver cancer sections (catalog applications and image captions). Its IHC staining is also shown in human placenta (catalog image caption).
Which to pick: Choose A01342-1 for human paraffin-section IHC; its captions report staining at 2 μg/ml after EDTA retrieval at pH 8.0 (catalog image captions). The captions do not report the fixative (catalog image captions). No listed SKU has IF/ICC validation or nonhuman reactivity, so this payload does not support an IF/ICC or cross-species pick (catalog applications and reactivity).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P22413 (ENPP1_HUMAN, Ectonucleotide pyrophosphatase/phosphodiesterase family member 1).
- Human Protein Atlas. ENPP1 tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. ENPP1 subcellular location (ICC-IF): Membrane, Secreted.
- Human Protein Atlas. ENPP1 antibody validation summary (2 antibodies).
- The molecular mechanism research of cartilage calcification induced by osteoarthritis. Bioengineered 2022 — PMC9276012.
- Identification of gene expression signature in estrogen receptor positive breast carcinoma. Biomarkers in cancer 2010 — PMC3783308.
- Osteopontin regulates dentin and alveolar bone development and mineralization. Bone 2018 — PMC5803363.
- Upregulation of IGF2 expression during vascular calcification. Journal of molecular endocrinology 2014 — PMC5610348.
- PubMed PMID:2211644 — UniProt-cited evidence.
- PubMed PMID:1315502 — UniProt-cited evidence.
- PubMed PMID:14574404 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for ENPP1 (Ectonucleotide pyrophosphatase/phosphodiesterase family member 1). Expected localisation Membranous staining in selected cells (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A01342-1). Validated IHC antibody: A01342-1 at 1-2 μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Parathyroid gland (Glandular cells); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human endometrial cancer tissue; fixative not specified (datasheet A01342-1); 2. Fixation: Image fixative and duration unreported (datasheet A01342-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A01342-1); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A01342-1); 8. Primary antibody: Rabbit anti-ENPP1, 1-2 μg/ml (datasheet A01342-1); 9. Primary incubation: Overnight at 4 °C (datasheet A01342-1). Watch for: Fixation: Keep fixation consistent across sections (standard IHC practice; not target-specific); Caveat: A secreted form may alter the expected membrane pattern (UniProt); Isoform / epitope: No listed isoforms; secreted form lacks the cytoplasmic region (UniProt); Regulation: Placenta-enhanced RNA expression (HPA tissue RNA). Evidence: UniProt P22413, HPA tissue IHC · Enhanced, HPA ICC-IF · Membrane, Secreted, Datasheet A01342-1, PMC9276012, PMC3783308. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/ENPP1/immunohistochemistry-ihc-guide.